BPC-157 research overview — structure, published in-vitro signaling, and the analytical documentation US laboratories expect on every batch.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. It is one of the most heavily researched stable gastric peptides in the Australia laboratory literature.
Structure
- Sequence: GEPPPGKPADDAGLV
- 15 amino acids, no disulfide bridges
- Average mass approximately 1419.5 Da
- Notable acid- and enzymatic-stability profile
Published research signaling
Published in-vitro and animal-model literature describes BPC-157 acting on multiple growth-factor and angiogenesis-related pathways, including modulation of VEGFR2 expression and nitric-oxide signaling. These findings are research observations only and do not establish therapeutic outcomes in humans.
What a verified BPC-157 COA shows
- ≥99% HPLC purity
- LC-MS confirmed exact mass
- Counterion (typically acetate) identity and percent
- Bacterial endotoxin per analytical method
Research use only. 3 Diamond Labs supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
